Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer. Its lead product candidate is Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor designed to address clinical challenges such as emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases in patients with ROS1-positive non-small cell lung cancer (NSCLC). This candidate is currently in the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial. Additionally, the company is developing Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor targeting resistance and CNS issues in ALK-positive cancers, which is in the Phase 2 portion of the ALKOVE-1 trial. Another candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor for tumors driven by HER2ex20 mutations, currently in Phase 1a/1b clinical trials.

Nuvalent, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NUVL. The trading currency for its shares is the US Dollar (USD). As a US-based company listed on a major US exchange, its stock is traded in USD, which is standard for companies listed on NasdaqGS. Investors looking to buy or sell NUVL shares will transact in US dollars, and the company's financial reports are also denominated in USD.

Nuvalent, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies, particularly for cancer treatment. The biotechnology industry involves using biological processes and organisms to create medical treatments, and Nuvalent's work in developing targeted inhibitors for cancer mutations places it squarely in this field. The company's clinical-stage pipeline includes therapies for non-small cell lung cancer and other tumors, highlighting its role in advancing precision medicine within the healthcare sector.

Nuvalent, Inc. is headquartered in Cambridge, Massachusetts, United States. The company was incorporated in 2017 and operates primarily in the US market. Its geographic focus is on developing therapies for patients with cancer, with a particular emphasis on addressing treatment resistance and brain metastases. While the company is US-based, its clinical trials and potential future markets may extend globally. The headquarters in Cambridge places it within a major biotech hub, providing access to research talent and partnerships, such as its strategic collaboration with Guardant Health, Inc. for developing companion diagnostics.

Nuvalent's pipeline includes three key product candidates. Zidesamtinib (NVL-520) is a novel ROS1-selective inhibitor for ROS1-positive non-small cell lung cancer (NSCLC), currently in the Phase 2 portion of the ARROS-1 trial. It aims to overcome treatment resistance, CNS adverse events, and brain metastases. Neladalkib (NVL-655) is a brain-penetrant ALK-selective inhibitor for ALK-positive cancers, in the Phase 2 portion of the ALKOVE-1 trial, targeting resistance and CNS issues. NVL-330 is a brain-penetrant HER2-selective inhibitor for tumors driven by HER2ex20 mutations, in Phase 1a/1b trials. These candidates are designed to improve upon existing therapies by addressing key clinical challenges.